Macaulay V.M., Lord S., Hussain S., Maroto J.P., Jones R.H., Climent M.Á., Cook N., Lin, CC, Wang, SS, Bianchini D., Bailey M., Schlieker L., Bogenrieder T., de Bono J.. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER. 2023; 129(6)DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:6.400(Q1/2D).

Isla, D, Sanchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabe, R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15)DOI:10.3390/jcm12155063. PMID:37568465. IF:3.000(Q1/2D).

Grunwald, V, Powles, T, Kopyltsov, E, Kozlov, V, Alonso-Gordoa, T, Eto, M, Hutson, T, Motzer, R, Winquist, E, Maroto, P, Keam, B, Procopio, G, Wong, SR, Melichar, B, Rolland, F, Oya, M, Rodriguez-Lopez, K, Saito, K, McKenzie, J, Porta, C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 2023; 6(4)DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8.300(Q1/1D).

Mayayo-Vallverdu, C, de Heredia, ML, Prat, E, Gonzalez, L, Guarch, ME, Vilches, C, Munoz, L, Asensi, MA, Serra, C, Llebaria, A, Casado, M, Artuch, R, Garrabou, G, Garcia-Roves, PM, Pallardo, FV, Nunes, V. The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Redox Biology. 2023; 64DOI:10.1016/j.redox.2023.102801. PMID:37418888. IF:10.700(Q1/1D).

Canto, E, Anguera, G, Jimenez, N, Mellado, B, Ramirez, O, Mariscal, A, Maroto, P, Vidal, S. Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment. Diagnostics. 2023; 13(13)DOI:10.3390/diagnostics13132222. PMID:37443615. IF:3.000(Q1/2D).

Giménez-Capitán A., Sánchez-Herrero E., de Lope, LR, Aguilar-Hernández A., Sullivan I., Calvo V., Moya-Horno I., Viteri S., Cabrera C., Aguado C., Armiger N., Valarezo J., Mayo-de-las-Casas C., Reguart N., Rosell R., Provencio M., Romero A., Molina-Vila M.A.. Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Molecular Oncology. 2023; 17(9)DOI:10.1002/1878-0261.13468. PMID:37243883. IF:5.000(Q1/3D).

Garcia-Saenz, JA, Blancas, I, Echavarria, I, Hinojo, C, Margeli, M, Moreno, F, Pernas, S, Cajal, T, Ribelles, N, Bellet, M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03229-y. PMID:37273149. IF:2.800(Q2/5D).

Tsuboi M., Herbst R.S., John T., Kato T., Majem M., Grohé C., Wang J., Goldman J.W., Lu S., Su, WC, De Marinis F., Shepherd F.A., Lee K.H., Le N.T., Dechaphunkul A., Kowalski D., Poole L., Bolanos A., Rukazenkov Y., Wu, YL. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(2)DOI:10.1056/NEJMoa2304594. PMID:37272535. IF:96.300(Q1/1D).

de Velasco G., Alonso-Gordoa T., Rodríguez-Vida A., Anguera G., Campayo M., Pinto Á., Ortega E.M., Gallardo E., Núñez N.F., García-Carbonero I., Reig O., Méndez-Vidal M.J., Fernández-Calvo O., Cassinello N.V., Torregrosa D., López-Martín A., Rosero A., Valiente P.G., de España C.G., Climent M.A., Santasusana M.D., Sánchez Á.R., González I.C., Afonso R., García del Muro X., Casinello J., Fernández-Parra E.M., García Sánchez L., Afonso J., Polo S.H., Asensio Ú.. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. Clinical Genitourinary Cancer. 2023; 21(3)DOI:10.1016/j.clgc.2022.11.021. PMID:36610891. IF:2.300(Q2/5D).

Roldan-Romero, JM, Valdivia, C, Santos, M, Lanillos, J, Maroto, P, Anguera, G, Calsina, B, Martinez-Montes, A, Monteagudo, M, Mellid, S, Leandro-Garcia, LJ, Montero-Conde, C, Cascon, A, Roncador, G, Coloma, J, Robledo, M, Rodriguez-Antona, C. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. INTERNATIONAL JOURNAL OF CANCER. 2023; 153(6)DOI:10.1002/ijc.34575. PMID:37260183. IF:5.700(Q1/2D).

Kobel, M, Kang, EY, Weir, A, Rambau, PF, Lee, CH, Nelson, GS, Ghatage, P, Meagher, NS, Riggan, MJ, Alsop, J, Anglesio, MS, Beckmann, MW, Bisinotto, C, Boisen, M, Boros, J, Brand, AH, Brooks-Wilson, A, Carney, ME, Coulson, P, Courtney-Brooks, M, Cushing-Haugen, KL, Cybulski, C, Deen, S, El-Bahrawy, MA, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Gayther, SA, Barquin-Garcia, A, Gentry-Maharaj, A, Gilks, CB, Gronwald, H, Grube, M, Harnett, PR, Harris, HR, Hartkopf, AD, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Huang, YJ, Jakubowska, A, Jimenez-Linan, M, Jones, ME, Kennedy, CJ, Kluz, T, Koziak, JM, Lesnock, J, Lester, J, Lubinski, J, Longacre, TA, Lycke, M, Mateoiu, C, McCauley, BM, McGuire, V, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Paz-Ares, L, Cajal, TRY, Rothstein, JH, Ruebner, M, Schoemaker, MJ, Shah, MT, Sharma, R, Sherman, ME, Shvetsov, YB, Singh, N, Steed, H, Storr, SJ, Talhouk, A, Traficante, N, Wang, C, Whittemore, AS, Widschwendter, M, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, dos Reis, FJC, Campbell, I, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Fortner, RT, Garcia, MJ, Goodman, MT, Goode, EL, Gronwald, J, Huntsman, DG, Karlan, BY, Kelemen, LE, Kommoss, S, Le, ND, Martin, SG, Menon, U, Modugno, F, Pharoah, PDP, Schildkraut, JM, Sieh, W, Staebler, A, Sundfeldt, K, Swerdlow, AJ, Ramus, SJ, Brenton, JD. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology Clinical Research. 2023; 9(3)DOI:10.1002/cjp2.311. PMID:36948887. IF:3.400(Q1/3D).

Remon, J, Besse, B, Aix, SP, Callejo, A, Al-Rabi, K, Bernabe, R, Greillier, L, Majem, M, Reguart, N, Monnet, I, Cousin, S, Garrido, P, Robinet, G, Campelo, RG, Madroszyk, A, Mazieres, J, Curcio, H, Wasag, B, Pretzenbacher, Y, Fournier, B, Dingemans, AMC, Dziadziuszko, R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. ANNALS OF ONCOLOGY. 2023; 34(5)DOI:10.1016/j.annonc.2023.02.012. PMID:36863484. IF:56.700(Q1/1D).

Lozano, R, Castro, E, -Campos, FL, Thorne, H, Ramirez-Backhaus, M, Aragon, IM, Cendon-Florez, Y, Gutierrez-Pecharroman, A, Salles, DC, Romero-Laorden, N, Lorente, D, Gonzalez-Peramato, P, Calatrava, A, Alonso, C, Anido, U, Arevalo-Lobera, S, Balmana, J, Chirivella, I, Juan-Fita, MJ, Llort, G, Cajal, TRY, Almagro, E, Alameda, D, Lopez-Casas, PP, Herrera, B, Mateo, J, Pritchard, CC, Antonarakis, ES, Lotan, TL, Rubio-Briones, J, Sandhu, S, Olmos, D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. EUROPEAN JOURNAL OF CANCER. 2023; 185DOI:10.1016/j.ejca.2023.02.022. PMID:36972661. IF:7.600(Q1/2D).

Sanfilippo, R, Hindi, N, Jurado, JC, Blay, JY, Lopez-Pousa, A, Italiano, A, Alvarez, R, Gutierrez, A, Rincon-Perez, I, Sangalli, C, Aguiar, JLP, Romero, J, Morosi, C, Sunyach, MP, Fabbroni, C, Romagosa, C, Ranchere-Vince, D, Dei Tos, AP, Casali, PG, Martin-Broto, J, Gronchi, A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial. JAMA Oncology. 2023; 9(5)DOI:10.1001/jamaoncol.2023.0056. PMID:36995731. IF:22.300(Q1/1D).

Martinez-Bosch, N, Vilarino, N, Alameda, F, Mojal, S, Arumi-Uria, M, Carrato, C, Aldecoa, I, Ribalta, T, Vidal, N, Bellosillo, B, Menendez, S, Del Barco, S, Gallego, O, Pineda, E, Lopez-Martos, R, Hernandez, A, Mesia, C, Esteve-Codina, A, de la Iglesia, N, Balana, C, Martinez-Garcia, M, Navarro, P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells. 2023; 12(6)DOI:10.3390/cells12060843. PMID:36980184. IF:5.100(Q2/4D).

Chmielecki, J, Gray, JE, Cheng, Y, Ohe, Y, Imamura, F, Cho, BC, Lin, MC, Majem, M, Shah, R, Rukazenkov, Y, Todd, A, Markovets, A, Barrett, JC, Hartmaier, RJ, Ramalingam, SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:14.700(Q1/1D).

Blay J.Y., Hindi N., Bollard J., Aguiar S., Jr., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Caro-Sánchez C.H.S., Carvajal B., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden V., Chacón M., Clara M., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., dei Tos A.P., Dominguez Malagon H.R., Donati D., Dufresne A., Eriksson M., Farias-Loza M., Fernandez P., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gelderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes David B.B., Lopez-Pousa A., Lutter G., Martinez-Said H., Martinez-Tlahuel J., Mello C.A., Morales Pérez J.M., Moura David S., Nascimento A.G., Ortiz-Cruz E.J., Palmerini E., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Salas R., Santos T.T.G., Scotlandi K., Soule T., Stacchiotti S., Valverde C., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312] (Cancer Treatment Reviews (2022) 102, (S0305737221001602), (10.1016/j.ctrv.2021.102312)). CANCER TREATMENT REVIEWS. 2023; 115DOI:10.1016/j.ctrv.2023.102523. PMID:36796283. IF:9.600(Q1/1D).

Pilcher, L, Pahlke, S, Urquhart, O, O'Brien, KK, Dhar, V, Fontana, M, Gonzalez-Cabezas, C, Keels, MA, Mascarenhas, AK, Nascimento, MM, Platt, JA, Sabino, GJ, Slayton, RL, Tinanoff, N, Young, DA, Zero, DT, Tampi, MP, Purnell, D, Salazar, J, Megremis, S, Bienek, D, Carrasco-Labra, A. Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION. 2023; 154(2)DOI:10.1016/j.adaj.2022.09.012. PMID:36610925. IF:3.100(Q1/2D).

Trilla-Fuertes L., Gámez-Pozo A., Prado-Vázquez G., López-Vacas R., Zapater-Moros A., López-Camacho E., Lumbreras-Herrera M.I., Soriano V., Garicano F., Lecumberri M.J., de la Borbolla, MR, Majem M., Pérez-Ruiz E., González-Cao M., Oramas J., Magdaleno A., Fra J., Martín-Carnicero A., Corral M., Puértolas T., Ramos R., Vara, JAF, Espinosa E.. Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1)DOI:10.3390/ijms24010801. PMID:36614248. IF:4.900(Q1/3D).

Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N., Tarruella, MM, Casas-Martin J., Tsourti Z., Marti N., Kammler R., Danson S., O'Brien M., Stahel R.A.. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. LUNG CANCER. 2023; 175DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:4.500(Q1/2D).

John T., Majem M., Legg D., Goldman J.. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Targeted Oncology. 2023; 18(1)DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:4.400(Q2/3D).

Blakely C.M., Weder W., Bubendorf L., He J., Majem M., Shyr Y., Chaft J.E.. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. LUNG CANCER. 2023; 177DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:4.500(Q1/2D).

Vidal J., Fernández-Rodríguez M.C., Casadevall D., García-Alfonso P., Páez D., Guix M., Alonso V., Cano M.T., Santos C., Durán G., Elez E., Manzano J.L., Garcia-Carbonero R., Ferreiro R., Losa F., Pineda E., Sastre J., Rivera F., Bellosillo B., Tabernero J., Aranda E., Salazar R., Montagut C.. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023; 29(2)DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:10.400(Q1/1D).

Martinez D.A.S., Quilez-Cutillas A., Jimenez-Labaig P., Sesma A., Tarazona N., Pacheco-Barcia V., Obispo B., Paez D., Quintanar T., Sanchez-Canovas M., Montes A.F., Felip E., Rodriguez-Lescure A., Elez E.. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:2.800(Q2/5D).

Chmielecki J., Gray J.E., Cheng Y., Ohe Y., Imamura F., Cho B.C., Lin M.-C., Majem M., Shah R., Rukazenkov Y., Todd A., Markovets A., Barrett J.C., Hartmaier R.J., Ramalingam S.S.. Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y). Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-38999-0. PMID:37263992. IF:14.700(Q1/1D).

Bertran-Alamillo J., Giménez-Capitán A., Román R., Talbot S., Whiteley R., Floc’h N., Martínez-Pérez E., Martin M.J., Smith P.D., Sullivan I., Terp M.G., Saeh J., Marino-Buslje C., Fabbri G., Guo G., Xu M., Tornador C., Aguilar-Hernández A., Reguart N., Ditzel H.J., Martínez-Bueno A., Nabau-Moretó N., Gascó A., Rosell R., Pease J.E., Polanska U.M., Travers J., Urosevic J., Molina-Vila M.A.. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1)DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27.700(Q1/1D).

Karachaliou N., Codony-Servat J., Teixidó C., Pilotto S., Drozdowskyj A., Codony-Servat C., Giménez-Capitán A., Molina-Vila M.A., Bertrán-Alamillo J., Gervais R., Massuti B., Morán T., Majem M., Felip E., Carcereny E., García-Campelo R., Viteri S., González-Cao M., Morales-Espinosa D., Verlicchi A., Crisetti E., Chaib I., Santarpia M., Luis Ramírez J., Bosch-Barrera J., Felipe Cardona A., de Marinis F., López-Vivanco G., Miguel Sánchez J., Vergnenegre A., Sánchez Hernández J.J., Sperduti I., Bria E., Rosell R.. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499). Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-30374-9. PMID:36869103. IF:3.800(Q1/2D).

De Castro J., Insa A., Collado-Borrell R., Escudero-Vilaplana V., Martínez A., Fernandez E., Sullivan I., Arrabal N., Carcedo D., Manzaneque A.. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine. 2023; 23(1)DOI:10.1186/s12890-023-02356-0. PMID:36809990. IF:2.600(Q2/5D).

Manzano J.L., Martin-Liberal J., Fernández-Morales L.A., Benítez G., Medina Martínez J., Quindós M., García-Castaño A., Fernández O., Simo R.V., Majem M., Bellido L., Ayala de Miguel P., Campos B., Espinosa E., Macías Cerrolaza J.A., Gil-Arnaiz I., Lorente D., Rodriguez-Lescure A., Perez V.N., López Castro R., Gramaje M.G., Puértolas T., Rodriguez Moreno J.F., Espasa Font L., Belaustegui Ferrández G., Cerezuela-Fuentes P.. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study. MELANOMA RESEARCH. 2023; 33(5)DOI:10.1097/CMR.0000000000000888. PMID:36988401. IF:1.500(Q3/7D).

Provencio M., Estival A., Franco F., López-Vivanco G., Saigí M., Arasanz H., Diz P., Carcereny E., García J., Aguado C., Mosquera J., Iruarrizaga E., Majem M., Bosch-Barrera J., Mielgo-Rubio X., Guirado M., Juan-Vidal Ó., Blasco A., Lucía Gozálvez C., Del Barrio A., De Portugal T., López-Martín A., Serrano G., Campos B., Rubio J., Catot S., Esteban B., Martí-Ciriquian J.L., del Barco E., Calvo V.. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4.500(Q1/2D).

O'Donnell P.H., Milowsky M.I., Petrylak D.P., Hoimes C.J., Flaig T.W., Mar N., Moon H.H., Friedlander T.W., McKay R.R., Bilen M.A., Srinivas S., Burgess E.F., Ramamurthy C., George S., Geynisman D.M., Bracarda S., Borchiellini D., Geoffrois L., Maroto Rey J.P., Ferrario C., Carret A.-S., Yu Y., Guseva M., Homet Moreno B., Rosenberg J.E.. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25)DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42.100(Q1/1D).

Blanco R., Dómine M., González J.L., Loutfi S., Alfaro J., Saldaña J., Rubio J., Campos B., Hidalgo J., Barba A., Márquez D., Martin M., Olaverri A., Nadal E.. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4.500(Q1/2D).

John T., Grohé C., Goldman J.W., Shepherd F.A., de Marinis F., Kato T., Wang Q., Su W.-C., Choi J.H., Sriuranpong V., Melotti B., Fidler M.J., Chen J., Albayaty M., Stachowiak M., Taggart S., Wu Y.-L., Tsuboi M., Herbst R.S., Majem M.. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. Journal of Thoracic Oncology. 2023; 18(9)DOI:10.1016/j.jtho.2023.05.015. PMID:37236398. IF:21.100(Q1/1D).

Tsutani Y., Goldman J.W., Dacic S., Yatabe Y., Majem M., Huang X., Chen A., van der Gronde T., He J.. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4)DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3.300(Q2/4D).

Herbst R.S., Wu Y.-L., John T., Grohe C., Majem M., Wang J., Kato T., Goldman J.W., Laktionov K., Kim S.-W., Yu C.-J., Vu H.V., Lu S., Lee K.Y., Mukhametshina G., Akewanlop C., De Marinis F., Bonanno L., Domine M., Shepherd F.A., Urban D., Huang X., Bolanos A., Stachowiak M., Tsuboi M.. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10)DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42.100(Q1/1D).

Provencio M., Ortega A.L., Coves-Sarto J., Calvo V., Marsé-Fabregat R., Dómine M., Guirado M., Carcereny E., Fernández N., Álvarez R., Blanco R., León-Mateos L., Sánchez-Torres J.M., Sullivan I.G., Cobo M., Sánchez-Hernández A., Massuti B., Sierra-Rodero B., Mártinez-Toledo C., Serna-Blasco R., Romero A., Cruz-Bermúdez A.. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3)DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22.300(Q1/1D).

Grünwald V., Powles T., Eto M., Kopyltsov E., Rha S.Y., Porta C., Motzer R., Hutson T.E., Méndez-Vidal M.J., Hong S.-H., Winquist E., Goh J.C., Maroto P., Buchler T., Takagi T., Burgents J.E., Perini R., He C., Okpara C.E., McKenzie J., Choueiri T.K.. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3.500(Q2/4D).

Fiala O., Buti S., Takeshita H., Okada Y., Massari F., Palacios G.A., Dionese M., Scagliarini S., Büttner T., Fornarini G., Myint Z.W., Galli L., Souza V.C., Pichler R., De Giorgi U., Quiroga M.N.G., Gilbert D., Popovic L., Grande E., Mammone G., Berardi R., Crabb S.J., Molina-Cerrillo J., Freitas M., Luz M., Iacovelli R., Calabrò F., Tural D., Atzori F., Küronya Z., Chiari R., Campos S., Caffo O., Fay A.P., Kucharz J., Zucali P.A., Rinck J.A., Zeppellini A., Bastos D.A., Aurilio G., Mota A., Trindade K., Ortega C., Sade J.P., Rizzo M., Vau N., Giannatempo P., Barillas A., Monteiro F.S.M., Dauster B., Cattrini C., Nogueira L., de Carvalho Fernandes R., Seront E., Aceituno L.G., Grillone F., Cutuli H.J., Fernandez M., Bassanelli M., Roviello G., Abahssain H., Procopio G., Milella M., Kopecky J., Martignetti A., Messina C., Caitano M., Inman E., Kanesvaran R., Herchenhorn D., Santini D., Manneh R., Bisonni R., Zakopoulou R., Mosca A., Morelli F., Maluf F., Soares A., Nunes F., Pinto A., Zgura A., Incorvaia L., Ansari J., Zabalza I.O., Landmesser J., Rizzo A., Mollica V., Sorgentoni G., Battelli N., Porta C., Bellmunt J., Santoni M.. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11)DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4.600(Q1/3D).

Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.-H., Gao S., Chen K.-N., Dooms C., Majem M., Eigendorff E., Martinengo G.L., Bylicki O., Rodríguez-Abreu D., Chaft J.E., Novello S., Yang J., Keller S.M., Samkari A., Spicer J.D.. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96.300(Q1/1D).

Tibau A., Martínez M.T., Ramos M., De La Cruz-Merino L., Santaballa A., O’Connor M., Martínez-Jañez N., Moreno F., Fernández I., Virizuela J.A., Alarcón J., de La Haba-Rodríguez J., Sánchez-Rovira P., Albacar C.R., Bueno Muiño C., Kelly C., Casas M., Bezares S., Rosell L., Albanell J.. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359221148921. PMID:36743520. IF:4.300(Q2/3D).